Key result
The 2026 ACC/AHA Dyslipidemia Guideline restores explicit LDL-C and non-HDL-C treatment goals stratified by ASCVD risk, emphasizing the critical role of analytical accuracy in lipid measurement.
Answers are grounded in this paper and cite their sources.
The 2026 ACC/AHA Dyslipidemia Guidelines restore explicit LDL-C and non-HDL-C treatment goals, elevating the importance of accurate clinical laboratory measurements in ASCVD risk management.
The 2026 American College of Cardiology/American Heart Association Multisociety Dyslipidemia Guideline (1) represents a substantial step forward from prior recommendations and elevates the role of the clinical laboratory in atherosclerotic cardiovascular disease (ASCVD) risk prediction and management (Table 1). The new framing of the guideline from management of “cholesterol” to “dyslipidemias” represents the conceptual shift from a cholesterol-centric view toward one that considers all atherogenic particles. The most consequential change is the restoration of explicit LDL cholesterol (LDL-C) as a treatment goal and the incorporation of non-HDL cholesterol (non-HDL-C) as a coprimary goal. Because therapy is once again “treat to goal,” the analytical accuracy of LDL-C and related ASCVD risk markers has become more critical than ever. The 2018 guideline deemphasized strict LDL-C targets, focusing instead on statin intensity and percentage LDL-C reduction, even while acknowledging the core principle that “lower is better.” The 2026 guideline reverses this trend by restoring explicit LDL-C and, for the first time, non-HDL-C goals stratified by ASCVD risk. For very-high-risk patients with established ASCVD, the new goal is LDL-C < 55 mg/dL (1.4 mmol/L) and non-HDL-C < 85 mg/dL (2.2 mmol/L); for high-risk primary prevention (10-year PREVENT risk ≥10%), <70 mg/dL and <100 mg/dL respectively; and for borderline-to-intermediate risk, <100 mg/dL and <130 mg/dL, respectively. From a clinical laboratory perspective, LDL-C is no longer just a risk factor; it is a tightly specified therapeutic endpoint. Thus, its accuracy directly influences the decision to add further lipid-lowering therapies, such as ezetimibe, PCSK9 inhibitors, bempedoic acid, or inclisiran to background statin therapy.
No takes yet. Share an insight, caveat, or question.
Zubiran et al. (2026) conducted a review in Dyslipidemia. 2026 ACC/AHA Multisociety Dyslipidemia Guideline vs. 2018 guideline was evaluated. The 2026 ACC/AHA Dyslipidemia Guideline restores explicit LDL-C and non-HDL-C treatment goals stratified by ASCVD risk, emphasizing the critical role of analytical accuracy in lipid measurement.
Synapse has enriched 10 related papers. Consider them for comparative context: